Supporting Information

Harzianumnones A and B: two hydroxyanthraquinones from the coral-derived fungus *Trichoderma harzianum*

Ting Shi,[a,b] Xue-Mei Hou,[a,b] Zhi-Yong Li,[c] Fei Cao,[d] Ya-Hui Zhang,[a,b] Jia-Yin Yu,[a,b] Dong-Lin Zhao,[a,b] Chang-Lun Shao,*[a,b] and Chang-Yun Wang,*[a,b,e]

Affiliation

[a] Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China

[b] Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266071, People's Republic of China

[c] Marine Biotechnology Laboratory, State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China

[d] Key Laboratory of Pharmaceutical Quality Control of Hebei Province, College of Pharmaceutical Sciences, Hebei University, Baoding 071002, People's Republic of China.

[e] Institute of Evolution & Marine Biodiversity, Ocean University of China, Qingdao 266003, People's Republic of China

Correspondence

* To whom correspondence should be addressed.

Tel/Fax: +86-531-82031536 (C.-Y. Wang); +86-532-82031381 (C.-L. Shao)

E-mail: changyun@ouc.edu.cn (C.-Y. Wang); shaochanglun@ouc.edu.cn (C.-L. Shao)

List of Supporting Information



Figure S1. ^{1}H NMR spectrum of compound **1** (DMSO-d_6).



Figure S2. ^{1}H NMR spectrum of compound **1** at the condition of spin (DMSO-d_6).



Figure S3. Partial ^{1}H NMR spectrum of compound **1** at the condition of spin (DMSO-d_6).



Figure S4. ^{13}C NMR spectrum of compound **1** (DMSO-d_6).



Figure S5. COSY spectrum of compound **1** (DMSO-d_6).



Figure S6. HSQC spectrum of compound **1** (DMSO-d_6).



Figure S7. HMBC spectrum of compound **1** (DMSO-d_6).



Figure S8. NOESY spectrum of compound **1** (DMSO-d_6)



Figure S9. ESIMS spectrum of compound **1**.



Figure S10. HRESIMS spectrum of compound **1**.



Figure S11. ^{1}H NMR spectrum of compound **2** (DMSO-d_6).



Figure S12. ^{13}C NMR spectrum of compound **2** (DMSO-d_6).



Figure S13. COSY spectrum of compound **2** (DMSO-d_6).



Figure S14. HSQC spectrum of compound **2** (DMSO-d_6).



Figure S15. HMBC spectrum of compound **2** (DMSO-d_6).



Figure S16. NOESY spectrum of compound **2** (DMSO-d_6)



Figure S17. ESIMS spectrum of compound **2**.



Figure S18. HRESIMS spectrum of compound **2**.



Figure S19. DNA Topo I inhibitory activity of compounds **5**–**9**. RLX: relaxed form; SC: supercoiled form; CPT: Camptothecin.

Table S1 Cytotoxic activity for compounds **5**, **7** and **8**

Compound	IC_{50} (μM)					
	HCT-116	SW480	A549	HepG2	Hela	PANC-1
5	35.3	28.6	>50	13.6	>50	>50
7	>50	39.0	>50	2.10	8.59	>50
8	29.8	>50	34.5	9.39	22.6	27.2
Adriamycin[a]	0.206	0.590	0.157	0.0365	0.602	0.498

[a] Adriamycin was used as a positive control.